Search filters

Filters
Clear All

Phase

  • 10
  • 15
  • 17
  • 11
  • 13
  • 70
  • 30
  • 3
  • 2
  • 65
  • 69
  • 1

Found 70 Chemotherapy trials

A listing of Chemotherapy medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)  A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
99 years or below
All genders
Phase 3
The purpose of this study is to find if adding the study drug, nivolumab (also known as OPVIDO), will limit lung cancer from growing back in patients with early stage non-small cell lung cancer. Nivolumab is a drug that may turn on the body's immune system to attack any cancer …
 Study to Assess the Efficacy and Safety of BST-236 in Adults Unfit for Intensive Chemotherapy with Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndromes
18 years - 99 years
All genders
Phase 2
Interventional
An open label multi center study to assess the safety and efficacy of BST-236 as single agent in adult patients unfit for standard therapy with Acute Myeloid Leukemia (AML) or higher-risk (HR) Myelodysplastic Syndromes (MDS) who fail to respond or relapsed following first line therapy.
 UPCC 06717 / AMC 101: A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas
18 years - 64 years
All genders
Phase 1
Non-Hodgkin lymphoma  is a potentially curable condition with standard cancer treatment drugs (chemotherapy) and steroids. Standard lymphoma treatment includes chemotherapy, or cancer-fighting drugs, called etoposide, vincristine, cyclophosphamide, prednisone and doxorubicin (called EPOCH).  
18 years - 99 years
All genders
Phase 2
The purpose of this study is to compare the effectiveness of gilteritinib to midostaurin in patients receiving standard combination chemotherapy for FLT3 AML. Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 65 will be randomized to receive gilteritinib or midostaurin during induction and …
 Phase 1 Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells (CART22-65s) alone and when co-administered with humanized Anti-CD19 Chimeric Antigen Receptor Redirected T cells (huCART19) In Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia
99 years or below
All genders
Phase 1
This is a single center, single arm, open-label Phase 1 study with two cohorts to determine the safety and feasibility of infusing CART22-65s with or without huCART19 after administration of lymphodepleting chemotherapy in adult patients with relapsed or refractory B-ALL.
18 years - 99 years
All genders
Phase 2
The purpose of this study is to see whether the addition of ixazomib to ibrutinib chemotherapy is effective in treating people who have relapsed or refractory mantle cell lymphoma and to examine the side effects associated with ixazomib in combination with ibrutinib.
 A Randomized  Open Label Pilot Trial of a Biomarker Guided Strategy of Cardioprotection in Patients with Lymphoma or Breast Cancer Treated with Anthracyclines
18 years - 99 years
All genders
Phase 1
You will be receiving anthracycline-based chemotherapy (Adriamycin/doxorubicin) as part of your cancer treatment plan. Although anthracycline-based chemotherapy is effective in treating cancer, it can damage your heart. This study has two goals. The first goal is to see if we can identify who is most at risk for this heart …
99 years or below
All genders
Phase 3
This is a study of the effectiveness and safety of giving the experimental drug, APR-246, together with the drug azacitidine to patients with MDS that has not yet been treated with chemotherapy or hypomethylating agents like azacitidine, compared with just giving azacitidine alone.
 EA2174: A Phase II/III Study of Peri-operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
18 years - 99 years
All genders
Phase 3
This phase II/III trial studies the usefulness of treatment with nivolumab and ipilimumab in addition to standard of care chemotherapy and radiation therapy in patients with esophageal and gastroesophageal junction adenocarcinoma who are undergoing surgery. This trial is open to Penn Medicine's Abramson Cancer Center patients only. Please contact the …
 Testing novel drugs or drug combinations to treat breast cancer before surgery
18 years - 99 years
Female
A clinical trial to determine whether adding experimental agents to standard neoadjuvant paclitaxel (with or without trastuzumab), anthracycline, nad cyclosphosphamide increases the probability of pathologic complete response (pCR) over standard neoadjuvant chemotherapy for each biomarker signature established at trial entry, and to determine for each experimental agent used, the predictive …